Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) COO Jr. Michael Conick Hanley sold 2,896 shares of the company’s stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $26.48, for a total transaction of $76,686.08. Following the transaction, the chief operating officer owned 17,729 shares in the company, valued at $469,463.92. The trade was a 14.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Jr. Michael Conick Hanley also recently made the following trade(s):
- On Monday, November 16th, Jr. Michael Conick Hanley sold 70,000 shares of Alto Neuroscience stock. The shares were sold at an average price of $27.68, for a total value of $1,937,600.00.
- On Tuesday, November 17th, Jr. Michael Conick Hanley sold 2,104 shares of Alto Neuroscience stock. The shares were sold at an average price of $26.82, for a total transaction of $56,429.28.
Alto Neuroscience Stock Up 3.4%
NYSE:ANRO traded up $0.85 during mid-day trading on Wednesday, hitting $25.77. The company’s stock had a trading volume of 986,145 shares, compared to its average volume of 597,641. Alto Neuroscience, Inc. has a 1 year low of $12.51 and a 1 year high of $37.48. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.12 and a quick ratio of 18.12. The business’s fifty day moving average is $25.83 and its two-hundred day moving average is $24.79.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.13. As a group, sell-side analysts anticipate that Alto Neuroscience, Inc. will post -2.48 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Alto Neuroscience
Large investors have recently made changes to their positions in the stock. Sterling Capital Management LLC lifted its position in Alto Neuroscience by 1,045.7% during the third quarter. Sterling Capital Management LLC now owns 1,054 shares of the company’s stock worth $27,000 after buying an additional 962 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in Alto Neuroscience by 48,581.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company’s stock valued at $137,000 after buying an additional 5,344 shares in the last quarter. GK Wealth Management LLC purchased a new stake in Alto Neuroscience in the 2nd quarter valued at $226,000. Empowered Funds LLC acquired a new stake in shares of Alto Neuroscience in the 3rd quarter worth $299,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Alto Neuroscience in the 1st quarter worth $534,000.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on ANRO. Zacks Research raised Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. BTIG Research restated a “buy” rating and issued a $37.00 price objective on shares of Alto Neuroscience in a report on Wednesday, November 11th. HC Wainwright reaffirmed a “buy” rating on shares of Alto Neuroscience in a research note on Thursday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a report on Tuesday, October 27th. Finally, Wedbush upped their target price on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.88.
Alto Neuroscience Company Profile
Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.
Further Reading
- Five stocks we like better than Alto Neuroscience
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
